GeoVax Bolsters Technical Leadership with Experienced Biologics Executive

Atlanta-based biotechnology company GeoVax Labs has strategically enhanced its technical leadership by appointing Dr. Senthil Ranganathan as Vice President of Technical Development and CMC Operations. The appointment underscores the company's commitment to advancing its portfolio of infectious disease vaccines and cancer therapies through seasoned scientific expertise.

Dr. Ranganathan brings over two decades of experience in biologics development, spanning vaccines, cell and gene therapies, monoclonal antibodies, and viral vector products. His extensive background includes senior leadership roles at prominent biopharmaceutical organizations, most recently serving as Head of Process Development CMC at National Resilience's Boston site.

The executive's arrival coincides with a critical growth phase for GeoVax, which is developing multiple clinical-stage programs. These include a next-generation COVID-19 vaccine targeting immunocompromised patients, an oncolytic solid tumor gene-directed therapy, and a vaccine addressing Mpox and smallpox.

GeoVax's CEO David Dodd emphasized the strategic importance of Dr. Ranganathan's expertise, noting his track record in preparing biologics for registration and commercialization will significantly support the company's ongoing development efforts. The appointment signals GeoVax's intent to strengthen its technical capabilities and potentially accelerate its path to bringing innovative medical solutions to market.

Dr. Ranganathan's professional history includes leadership positions at Athersys, Zymeworks, and Alder Biopharmaceuticals, where he guided the development and validation of complex biological therapeutics. His academic credentials include a Ph.D. in Biochemistry from Loyola University Chicago, complemented by numerous regulatory submissions and scientific publications.

The strategic hiring comes at a pivotal moment for GeoVax, as the company seeks to address unmet medical needs, contribute to biodefense readiness, and improve vaccine and therapeutic equity through innovative onshore development strategies. Dr. Ranganathan's appointment represents a significant investment in the company's technical infrastructure and future potential.